Tissue | Expression Dynamics | Abbreviation |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/FKBP4_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/FKBP4_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/FKBP4_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/FKBP4_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
GC | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/GC/FKBP4_pca_on_diff_genes.png) | CAG: Chronic atrophic gastritis |
CAG with IM: Chronic atrophic gastritis with intestinal metaplasia |
CSG: Chronic superficial gastritis |
GC: Gastric cancer |
SIM: Severe intestinal metaplasia |
WIM: Wild intestinal metaplasia |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/FKBP4_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/FKBP4_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/FKBP4_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/FKBP4_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/FKBP4_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00311103 | Oral cavity | OSCC | regulation of microtubule polymerization or depolymerization | 47/7305 | 88/18723 | 4.23e-03 | 1.72e-02 | 47 |
GO:190290417 | Oral cavity | OSCC | negative regulation of supramolecular fiber organization | 81/7305 | 167/18723 | 7.70e-03 | 2.82e-02 | 81 |
GO:00313458 | Oral cavity | OSCC | negative regulation of cell projection organization | 89/7305 | 186/18723 | 8.51e-03 | 3.09e-02 | 89 |
GO:000645719 | Oral cavity | LP | protein folding | 125/4623 | 212/18723 | 1.62e-26 | 8.45e-24 | 125 |
GO:006107719 | Oral cavity | LP | chaperone-mediated protein folding | 45/4623 | 67/18723 | 2.58e-13 | 2.41e-11 | 45 |
GO:0043254110 | Oral cavity | LP | regulation of protein-containing complex assembly | 163/4623 | 428/18723 | 3.72e-10 | 1.92e-08 | 163 |
GO:0051258110 | Oral cavity | LP | protein polymerization | 113/4623 | 297/18723 | 1.90e-07 | 5.92e-06 | 113 |
GO:001063919 | Oral cavity | LP | negative regulation of organelle organization | 127/4623 | 348/18723 | 5.07e-07 | 1.40e-05 | 127 |
GO:0032271110 | Oral cavity | LP | regulation of protein polymerization | 89/4623 | 233/18723 | 3.00e-06 | 6.47e-05 | 89 |
GO:1902903110 | Oral cavity | LP | regulation of supramolecular fiber organization | 131/4623 | 383/18723 | 1.58e-05 | 2.78e-04 | 131 |
GO:001820815 | Oral cavity | LP | peptidyl-proline modification | 28/4623 | 58/18723 | 8.35e-05 | 1.07e-03 | 28 |
GO:000041312 | Oral cavity | LP | protein peptidyl-prolyl isomerization | 22/4623 | 42/18723 | 1.04e-04 | 1.26e-03 | 22 |
GO:004678512 | Oral cavity | LP | microtubule polymerization | 34/4623 | 83/18723 | 7.88e-04 | 6.99e-03 | 34 |
GO:003133319 | Oral cavity | LP | negative regulation of protein-containing complex assembly | 52/4623 | 141/18723 | 8.28e-04 | 7.24e-03 | 52 |
GO:007050715 | Oral cavity | LP | regulation of microtubule cytoskeleton organization | 53/4623 | 148/18723 | 1.60e-03 | 1.23e-02 | 53 |
GO:190290418 | Oral cavity | LP | negative regulation of supramolecular fiber organization | 56/4623 | 167/18723 | 6.19e-03 | 3.66e-02 | 56 |
GO:003134513 | Oral cavity | LP | negative regulation of cell projection organization | 61/4623 | 186/18723 | 7.59e-03 | 4.18e-02 | 61 |
GO:003111314 | Oral cavity | LP | regulation of microtubule polymerization | 22/4623 | 55/18723 | 8.69e-03 | 4.69e-02 | 22 |
GO:004325426 | Oral cavity | EOLP | regulation of protein-containing complex assembly | 112/2218 | 428/18723 | 1.58e-16 | 1.35e-13 | 112 |
GO:190290326 | Oral cavity | EOLP | regulation of supramolecular fiber organization | 93/2218 | 383/18723 | 6.50e-12 | 1.08e-09 | 93 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0491520 | Cervix | CC | Estrogen signaling pathway | 44/1267 | 138/8465 | 3.55e-07 | 3.97e-06 | 2.35e-06 | 44 |
hsa04915110 | Cervix | CC | Estrogen signaling pathway | 44/1267 | 138/8465 | 3.55e-07 | 3.97e-06 | 2.35e-06 | 44 |
hsa04915 | Colorectum | SER | Estrogen signaling pathway | 38/1580 | 138/8465 | 6.51e-03 | 3.68e-02 | 2.67e-02 | 38 |
hsa049151 | Colorectum | SER | Estrogen signaling pathway | 38/1580 | 138/8465 | 6.51e-03 | 3.68e-02 | 2.67e-02 | 38 |
hsa049152 | Colorectum | MSS | Estrogen signaling pathway | 48/1875 | 138/8465 | 4.23e-04 | 3.08e-03 | 1.89e-03 | 48 |
hsa049153 | Colorectum | MSS | Estrogen signaling pathway | 48/1875 | 138/8465 | 4.23e-04 | 3.08e-03 | 1.89e-03 | 48 |
hsa049154 | Colorectum | CRC | Estrogen signaling pathway | 29/1091 | 138/8465 | 4.83e-03 | 2.66e-02 | 1.80e-02 | 29 |
hsa049155 | Colorectum | CRC | Estrogen signaling pathway | 29/1091 | 138/8465 | 4.83e-03 | 2.66e-02 | 1.80e-02 | 29 |
hsa0491529 | Oral cavity | EOLP | Estrogen signaling pathway | 38/1218 | 138/8465 | 3.78e-05 | 1.82e-04 | 1.07e-04 | 38 |
hsa04915113 | Oral cavity | EOLP | Estrogen signaling pathway | 38/1218 | 138/8465 | 3.78e-05 | 1.82e-04 | 1.07e-04 | 38 |
hsa0491527 | Prostate | BPH | Estrogen signaling pathway | 48/1718 | 138/8465 | 4.60e-05 | 3.16e-04 | 1.96e-04 | 48 |
hsa04915112 | Prostate | BPH | Estrogen signaling pathway | 48/1718 | 138/8465 | 4.60e-05 | 3.16e-04 | 1.96e-04 | 48 |
hsa0491528 | Prostate | Tumor | Estrogen signaling pathway | 48/1791 | 138/8465 | 1.36e-04 | 8.33e-04 | 5.17e-04 | 48 |
hsa0491536 | Prostate | Tumor | Estrogen signaling pathway | 48/1791 | 138/8465 | 1.36e-04 | 8.33e-04 | 5.17e-04 | 48 |
hsa0491512 | Stomach | GC | Estrogen signaling pathway | 23/708 | 138/8465 | 1.02e-03 | 7.44e-03 | 5.23e-03 | 23 |
hsa0491513 | Stomach | GC | Estrogen signaling pathway | 23/708 | 138/8465 | 1.02e-03 | 7.44e-03 | 5.23e-03 | 23 |
hsa0491521 | Stomach | CAG with IM | Estrogen signaling pathway | 21/640 | 138/8465 | 1.53e-03 | 1.01e-02 | 7.10e-03 | 21 |
hsa0491531 | Stomach | CAG with IM | Estrogen signaling pathway | 21/640 | 138/8465 | 1.53e-03 | 1.01e-02 | 7.10e-03 | 21 |
hsa0491541 | Stomach | CSG | Estrogen signaling pathway | 20/633 | 138/8465 | 3.10e-03 | 1.88e-02 | 1.35e-02 | 20 |
hsa0491551 | Stomach | CSG | Estrogen signaling pathway | 20/633 | 138/8465 | 3.10e-03 | 1.88e-02 | 1.35e-02 | 20 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
FKBP4 | SNV | Missense_Mutation | | c.557G>A | p.Arg186Gln | p.R186Q | Q02790 | protein_coding | deleterious(0) | probably_damaging(0.985) | TCGA-A2-A0CL-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cytoxan | SD |
FKBP4 | SNV | Missense_Mutation | novel | c.1223N>G | p.Lys408Arg | p.K408R | Q02790 | protein_coding | tolerated(0.26) | benign(0.159) | TCGA-A7-A4SD-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | CR |
FKBP4 | SNV | Missense_Mutation | novel | c.766N>C | p.Lys256Gln | p.K256Q | Q02790 | protein_coding | deleterious(0) | possibly_damaging(0.881) | TCGA-BH-A0HU-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | docetaxel | SD |
FKBP4 | SNV | Missense_Mutation | | c.1108G>A | p.Glu370Lys | p.E370K | Q02790 | protein_coding | deleterious(0.04) | benign(0.058) | TCGA-EA-A1QS-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
FKBP4 | SNV | Missense_Mutation | | c.823G>C | p.Glu275Gln | p.E275Q | Q02790 | protein_coding | tolerated(0.08) | benign(0.428) | TCGA-EK-A2H0-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
FKBP4 | SNV | Missense_Mutation | | c.26C>T | p.Thr9Ile | p.T9I | Q02790 | protein_coding | tolerated(0.18) | benign(0.017) | TCGA-Q1-A73P-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
FKBP4 | SNV | Missense_Mutation | | c.823G>C | p.Glu275Gln | p.E275Q | Q02790 | protein_coding | tolerated(0.08) | benign(0.428) | TCGA-ZJ-A8QQ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD |
FKBP4 | SNV | Missense_Mutation | novel | c.976G>T | p.Ala326Ser | p.A326S | Q02790 | protein_coding | deleterious(0.04) | possibly_damaging(0.59) | TCGA-ZJ-AAX8-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unknown | Unknown | SD |
FKBP4 | insertion | Frame_Shift_Ins | novel | c.372dupC | p.Asn125GlnfsTer7 | p.N125Qfs*7 | Q02790 | protein_coding | | | TCGA-EA-A3HU-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
FKBP4 | SNV | Missense_Mutation | rs766636474 | c.1343N>T | p.Thr448Met | p.T448M | Q02790 | protein_coding | tolerated_low_confidence(0.16) | benign(0) | TCGA-A6-2686-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |